Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Benign prostatic hyperplasia

Countering proliferation and inflammation naturally

    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • RX
    • Urology
  • 3 minute read

Benign prostatic hyperplasia is a common urological condition caused by non-malignant enlargement of the prostate. About one-third of men over 40 report lower urinary tract problems in this context. A phytotherapeutic combination of active ingredients significantly reduces prostate cell proliferation and also shows an anti-inflammatory effect.

Benign enlargement of the prostate gland (BPH) often presents in aging men. The inner part of the prostate enlarges and can squeeze the urethra. It is not uncommon for lower urinary tract symptoms (LUTS), such as discomfort during urination, to then occur. Between the ages of 51 and 60, half of men suffer from it, and in men over 80 it is already up to 90%. At the histologic level, BPH is characterized by hyperproliferation of both stromal and glandular cell compartments in the transition zone and periurethral areas of the prostate. Medical treatment of LUTS therefore aims to reduce cell proliferation by inhibiting 5α-reductase enzymes involved in the conversion of testosterone to its active metabolite dihydrotestosterone (DHT). Bladder overactivity and smooth prostate tone should also be lowered. A variety of treatment options are available with α-blockers, 5α-reductase inhibitors (5ARIs), antimuscarinics, phosphodiesterase type 5 inhibitors (PDE5Is), and herbal medicines. However, these have not yet been able to influence the progression of the disease.

In recent years, it has been demonstrated that an increase in immune cells in the hyperplastic prostate is a risk factor for disease progression. A clear relationship between chronic prostatic inflammation, LUTS severity, and acute urinary retention was established. However, the underlying biochemical pathways are very complex, but indicate that inflammation is of interest as a therapeutic target.

Phytotherapy on the test bench

Therefore, for the phytopharmaceutical drug combination of a lipophilic extract from fruits of Sabal serrulata and an aqueous ethanolic extract from roots of Urtica dioica (Prostagutt forte®), the growth and anti-inflammatory properties were investigated with regard to the progression of BPH in the mouse model. Both components have a very long tradition as herbal remedies in folk medicine in Europe and the USA. Lipophilic extracts of saw palmetto fruit exert multiple mechanisms of action, including antiandrogenic, anti-inflammatory, anti-edematous, spasmolytic, and antiproliferative effects. These activities are mediated by inhibition of 5α-reductase, dual inhibition of cyclooxygenase and 5-lipoxygenase, inhibition of α1-adrenoceptors, and inhibition of growth factors. For aqueous ethanolic nettle root extracts, inhibition of aromatase, inhibition of leukocyte elastase, and inhibition of membrane Na+ – and K+ -ATPase activity that may restrict prostate cells are also discussed.

The transgenic probasin-prolactin (Pb-PRL) mouse model, in which prostate-specific overexpression of PRL leads to several features of human disease, including tissue hypertrophy, epithelial hyperplasia, increased stromal cellularity, inflammation, and LUTS, was used for the study. Six-month-old heterozygous male Pb-PRL mice were randomly divided into five groups that received either the drug combination at different doses (300, 600, or 900 mg/kg/day), the 5α-reductase inhibitor finasteride (5 mg/kg/day), or vehicle (olive oil 5 ml/kg/day) for 28 consecutive days. There was good tolerability of oral treatment and a dose-dependent reduction in prostate weight. This effect was accompanied by a reduction in prostate cell proliferation as assessed by lower Ki-67 expression (qPCR and immunohistochemistry). In contrast, finasteride had little or no effect on these parameters. The growth inhibitory effect of the phytotherapeutic was accompanied by a strong anti-inflammatory effect, as evidenced by the decreased infiltration of cells expressing the common leukocyte antigen CD45. Finasteride, on the other hand, significantly increased inflammatory status.

 

Further reading:

  • Pigat N, Reyes-Gomez E, Boutillon F, et al: Combined Sabal and Urtica Extracts (WSR 1541) Exert Anti-proliferative and Anti-inflammatory Effects in a Mouse Model of Benign Prostate Hyperplasia. Front. Pharmacol. 2019; 10:311.

 

GP PRACTICE 2020; 15(2): 33

Publikation
  • HAUSARZT PRAXIS
Related Topics
  • BPH
  • LUTS
  • prostate hyperplasia
Previous Article
  • Stock investment

Corona crash: what now?

  • Infectiology
  • News
  • RX
View Post
Next Article
  • Breast Cancer

Anesthesia has no effect on recurrence risk

  • Anesthesiology
  • Education
  • Gynecology
  • News
  • Oncology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 3 min
  • From symptom to diagnosis

Abdominal pain – groin pain: internal causes

    • Cases
    • Education
    • Gynecology
    • Radiology
    • RX
    • Surgery
    • Urology
View Post
  • 2 min
  • Chronic pain

Nano-ECS modulator Adezunap improves therapy success

    • Congress Reports
    • General Internal Medicine
    • Pharmaceutical medicine
    • Pharmacology and toxicology
    • Phytotherapy
    • Rheumatology
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis and PsA

Biologics, oral peptide and trivalent nanobody – current results and trends

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • Rheumatology
    • RX
    • Studies
View Post
  • 5 min
  • Cancer in Europe: facts and analysis

New Health Policy Report published

    • General Internal Medicine
    • Oncology
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 4 min
  • Gastrointestinal complaints

PPI regulation under the microscope

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 6 min
  • Wound management: clinical diagnostics

Assessing the risk of infection – from the ABCDE to the TILI score

    • Congress Reports
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Geriatrics
    • Infectiology
    • Interviews
    • Physical medicine and rehabilitation
    • Prevention and health care
    • RX
View Post
  • 4 min
  • Study report

Digital patient education for atrial fibrillation shows measurable effects

    • Cardiology
    • Education
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 4 min
  • New practice guideline for fibromyalgia syndrome

Good times, bad times

    • Congress Reports
    • General Internal Medicine
    • Neurology
    • Pharmacology and toxicology
    • Physical medicine and rehabilitation
    • Rheumatology
    • RX
    • Sports Medicine
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    How combination therapies lead to better treatment results
  • 2
    Interplay between cancer and mental illness
  • 3
    PH and lung diseases
  • 4
    Treatment of comorbidities in older people
  • 5
    Multidisciplinary teams in oncology

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.